A Phase II Study of Weekly ABRAXANE(R) (Nab-paclitaxel) for Patients With Advanced NSCLC With EGFR Mutations Following Front-line Therapy With EGFR Tyrosine Kinase Inhibitors
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Jun 2021 Status changed from active, no longer recruiting to completed.
- 28 Feb 2019 Planned End Date changed from 23 May 2027 to 20 Apr 2021.
- 28 Feb 2019 Planned primary completion date changed from 23 May 2024 to 20 Apr 2021.